Inactief instrument

Koers Tobira Therapeutics Inc Nasdaq

Aandelen

Duur

Periode

Stijl

TOBIRA fait gagner plus de 40 000 euros à un investisseur !	26-10-16
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20-10-16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03-10-16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21-09-16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20-09-16

Managers	Titel	Leeftijd	Van
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Sector

	Vaira. 1 jan.	Kapi.
REGENERON PHARMACEUTICALS, INC.	+8,96%	105 mld.
VERTEX PHARMACEUTICALS INCORPORATED	-1,43%	104 mld.
ARGENX SE	+4,40%	22,94 mld.
BIONTECH SE	-12,15%	22,34 mld.
GENMAB A/S	-4,36%	19,25 mld.
WUXI APPTEC CO., LTD.	-39,98%	17,08 mld.
BEIGENE, LTD.	-10,04%	16,96 mld.
SAREPTA THERAPEUTICS, INC.	+38,61%	12,63 mld.
VIKING THERAPEUTICS, INC.	+313,59%	8,49 mld.